ENVASARC (Sarcoma) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to see if the study drug, envafolimab, when given alone or in combination with ipilimuma, can stimulate your immune system to attack cancer cells.
We also want to learn more about the effectiveness and safety of the study drug.
Advanced or metastatic Undifferentiated Pleomorphic Sarcoma (UPS) or Myxofibrosarcoma (MFS)
Who Can Participate in the Study?
-Have a diagnosis of locally advanced, unresectable or metastatic UPS or Grade 2 (or higher) MFS
For more information on who can participate in this study please contact the study team.
What is Involved?
If you choose to join this study, you will:
-Have physical exams and blood draws
-Be assigned to either Group 1 or Group 2 (a fair 50/50 chance):
--Group 1 will get the study drug (Envafolimab) once every three weeks on days 1 and 22 of every 42-day cycle through an injection under your skin for about 30 seconds.
--Group 2 will get the study drug (Envafolimab) once every three weeks on days 1 and 22 of every 42-day cycle, and Ipilimumab into your vein once every three weeks on days 1 and 22 of cycles 1 and 2 only
Both groups will:
-Continue to receive follow-up about 28 days after you stop the treatments
-Get a phone call every 3 months after the last dose of medicine to see how you are feeling